First Ticketmaster provoked the ire of Swifties — fans of pop star Taylor Swift — and now it's coming for another group of devotees in decidedly darker clothing: fans of The Cure.
Anyone who attempted to purchase Verified Fan presale tickets on Wednesday was met with an array of added fees that, in some cases, more than doubled the total cost of a ticket to see the legendary English new wave band.
One Twitter user buying tickets to a show in Detroit shared a screenshot of a checkout page showing that for each $20 face-value ticket purchased, she was charged a service fee of $11.65 and a facility charge of $10, topped off with a processing fee of $5.50 for the full order. That's $27.15 in fees on a $20 ticket.
The Cure frontman Robert Smith took to Twitter later that day to express his dismay with the fees writing, "To be very clear: The artist has no way to limit them. I have been asking how they are justified."
Range of tickets prices offered
On March 10, The Cure announced via social media it would be offering affordable tickets for its North American tour, writing, “We have a very wide (and we think very fair) range of pricing at every show.” The band said it had come up with an agreement with Ticketmaster to help stop ticket scalping and minimize resale price gouging by not allowing for transferable tickets. Fans would instead be able to resell them on a face-value ticket exchange.
The Cure also announced there would be no “platinum” or “dynamically priced” tickets for the 30-date tour, which kicks off on May 10 in New Orleans. On Twitter, Smith referred to these higher price ticket levels as “a greedy scam.”
For comparison, face-value ticket prices for Bad Bunny, 2022’s top touring act (according to Billboard), averaged more than $200, with the lowest tier coming in at about $150.
The upset among Cure fans comes four months after Ticketmaster abruptly canceled its public sale of tickets for Swift’s long-awaited Eras tour after technical difficulties, long wait times, and, ultimately, prematurely outselling its inventory of tickets through a multitiered presale for Verified Fans. All the while, resellers posted tickets for tens of thousands of dollars. The move prompted disappointed Swifties to file a class-action lawsuit accusing Ticketmaster of fraud, misrepresentation and antitrust violations.
Biden and Congress eye junk fees
In November, President Joe Biden announced that he planned to take action against hidden junk fees, specifically referencing processing fees on concert tickets, tweeting “they’re unfair, deceptive, and add up.” Then, in February, Biden introduced the Junk Fee Prevention Act, which would crack down on excessive entertainment ticketing fees.
In a White House press release, Biden called on Congress to take action by prohibiting excess fees, requiring fees to be disclosed in the face value of the ticket, and mandating disclosure of any ticket holdbacks that would lower available supply for consumers.
Congress is taking notice. On Feb. 23, members of a Senate Judiciary subcommittee overseeing competition policy urged the Department of Justice’s Antitrust Division to investigate Live Nation and Ticketmaster over concerns they hold monopoly power. In a letter to the DOJ, the group of bipartisan senators wrote, “For too long, Live Nation and Ticketmaster have wielded monopoly power anticompetitively, harming fans and artists alike.” The letter followed a January hearing by the Senate Judiciary Committee that delved into the Taylor Swift ticketing debacle.
Live Nation Entertainment — formed by the 2010 merger of Live Nation and Ticketmaster — reportedly owns an estimated 70% of the live event ticket brokering market, according to consumer advocates.
More From NerdWallet
- Have a Job and a Side Gig? Watch for These Missteps
- How Being Neurodiverse Affects Your Relationship With Money
- How to Fight the ‘Pink Tax’ Amid Inflation
The article The Cure’s Ticket Prices Spike With Ticketmaster Fees originally appeared on NerdWallet.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.